Theoretical pharmacokinetic advantages and methodological flaws: glargine is not superior to NPH insulin in children with type 1 diabetes mellitus.
Dora
José Miguel
JM
Scheffel
Rafael S
RS
D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D007223:Infant; D007231:Infant, Newborn; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000009:adverse effects* / Q000493:pharmacokinetics; D049528:Insulin, Long-Acting; D012107:Research Design / Q000592:standards*
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting